Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| OmniAb, Inc.OABI · Entity 5294 | Director | June 23, 2023 | June 27, 2023 |
| OncoMed Pharmaceuticals IncOMED · Entity 158190 | See Remarks | January 04, 2018 | January 08, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
OmniAb, Inc.
Report date June 23, 2023 · Filed June 27, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 20,000 |
Reported balance
After 2023-06-23 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-06-23 · Grant · Acquired 20,000 · Balance 20,000 F1: Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs shall vest in full on the earlier of (A) the date of the next annual meeting of the Company's stockholders following the grant date and (B) the first anniversary of the date of grant. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.81 · Expires 2033-06-23 | Direct | 40,000 |
Reported balance
After 2023-06-23 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-06-23 · Grant · Acquired 40,000 · Balance 40,000 F2: Each Stock Option shall vest and become exercisable in full on the earlier of (A) the date of the annual meeting of the Company's stockholders next following the grant date and (B) on the first anniversary of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs shall vest in full on the earlier of (A) the date of the next annual meeting of the Company's stockholders following the grant date and (B) the first anniversary of the date of grant.
F2: Each Stock Option shall vest and become exercisable in full on the earlier of (A) the date of the annual meeting of the Company's stockholders next following the grant date and (B) on the first anniversary of the date of grant.
OncoMed Pharmaceuticals Inc
Report date January 04, 2018 · Filed January 08, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.98 · Expires 2028-01-03 | Direct | 100,000 |
Reported balance
After 2018-01-04 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-01-04 · Grant · Acquired 100,000 · Balance 100,000 F1: The option vests with respect to 1/48 of the shares subject thereto on each monthly anniversary of the date of grant, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests with respect to 1/48 of the shares subject thereto on each monthly anniversary of the date of grant, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
LIGAND PHARMACEUTICALS INC
Report date November 01, 2022 · Filed November 04, 2022
Section 16 reporting ended · disclosed 2022-11-04. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 28,820 |
Reported balance
After 2022-11-01 transaction · row 1
1 source rowRow 1 · 2022-11-01 · Disposition to issuer · Disposed 1,004 · Balance 28,820 F1: Certain of the Reporting Person's equity awards were cancelled in connection with the separation of OmniAb, Inc. from the Issuer on November 1, 2022. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $90.68 · Expires 2032-06-10 | Direct | 0 |
Reported balance
After 2022-11-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-11-01 · Disposition to issuer · Disposed 4,340 · Balance 0 F1: Certain of the Reporting Person's equity awards were cancelled in connection with the separation of OmniAb, Inc. from the Issuer on November 1, 2022. F2: The stock option vests and is exercisable on the earlier of (i) the date of the next annual meeting of the Issuer's stockholders following the grant date or (ii) on June 10, 2023. |
Filing footnotes · ownership attribution and instrument terms
F1: Certain of the Reporting Person's equity awards were cancelled in connection with the separation of OmniAb, Inc. from the Issuer on November 1, 2022.
F2: The stock option vests and is exercisable on the earlier of (i) the date of the next annual meeting of the Issuer's stockholders following the grant date or (ii) on June 10, 2023.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 23, 2023 Filed Jun 27, 2023 18:11 UTC | OmniAb, Inc. OABI · Entity 5294 | GrantStock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $4.81 | $0.00 |
DisclosureSEC source: 0001846253-23-000086 · primary_doc.xml · derivative · entry 2 Patel Sunil · CIK 0001503062 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2033-06-23 F2 · derivative.exercise_date: Each Stock Option shall vest and become exercisable in full on the earlier of (A) the date of the annual meeting of the Company's stockholders next following the grant date and (B) on the first anniversary of the date of grant. Read SEC document |
| June 23, 2023 Filed Jun 27, 2023 18:11 UTC | OmniAb, Inc. OABI · Entity 5294 | GrantRestricted Stock Units · Derivative | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001846253-23-000086 · primary_doc.xml · derivative · entry 1 Patel Sunil · CIK 0001503062 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs shall vest in full on the earlier of (A) the date of the next annual meeting of the Company's stockholders following the grant date and (B) the first anniversary of the date of grant. F1 · derivative.exercise_date: Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs shall vest in full on the earlier of (A) the date of the next annual meeting of the Company's stockholders following the grant date and (B) the first anniversary of the date of grant. F1 · derivative.expiration_date: Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs shall vest in full on the earlier of (A) the date of the next annual meeting of the Company's stockholders following the grant date and (B) the first anniversary of the date of grant. Read SEC document |
| January 30, 2023 Filed Feb 1, 2023 14:29 UTC | OmniAb, Inc. OABI · Entity 5294 | GrantStock Option · Derivative | 37,840 | $0.00 Strike: $4.25 | $0.00 |
DisclosureSEC source: 0001846253-23-000012 · edgardoc.xml · derivative · entry 2 Patel Sunil · CIK 0001503062 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,840 Underlying: Common Stock · 37,840 shares Expires 2033-01-30 F2 · derivative.exercise_date: The stock option fully vests on the earlier of (i) the date of the next annual meeting of the Issuer's stockholders or (ii) on the first Grant Date Anniversary. Read SEC document |
| January 30, 2023 Filed Feb 1, 2023 14:29 UTC | OmniAb, Inc. OABI · Entity 5294 | GrantCommon Stock | 8,753 | $0.00 | $0.00 |
DisclosureSEC source: 0001846253-23-000012 · edgardoc.xml · nonDerivative · entry 1 Patel Sunil · CIK 0001503062 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 224,265 F1 · shares: Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSU fully vests on the earlier of (i) the date of the next annual meeting of the Issuer's stockholders or (ii) on the first Grant Date Anniversary. Read SEC document |
| November 09, 2022 Filed Nov 10, 2022 18:45 UTC | OmniAb, Inc. OABI · Entity 5294 | PurchaseCommon Stock | 43,000 | $2.77 | $119,110.00 |
DisclosureSEC source: 0000899243-22-035565 · doc4.xml · nonDerivative · entry 1 Patel Sunil · CIK 0001503062 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 215,512 Read SEC document |
| November 01, 2022 Filed Nov 4, 2022 01:06 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 4,340 | Not disclosed Strike: $90.68 | Not disclosed |
DisclosureSEC source: 0000899243-22-035039 · doc4.xml · derivative · entry 2 Patel Sunil · CIK 0001503062 · Former Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,340 shares Expires 2032-06-10 F1 · kind: Certain of the Reporting Person's equity awards were cancelled in connection with the separation of OmniAb, Inc. from the Issuer on November 1, 2022. F1 · price: Certain of the Reporting Person's equity awards were cancelled in connection with the separation of OmniAb, Inc. from the Issuer on November 1, 2022. F2 · derivative.exercise_date: The stock option vests and is exercisable on the earlier of (i) the date of the next annual meeting of the Issuer's stockholders following the grant date or (ii) on June 10, 2023. Read SEC document |
| November 01, 2022 Filed Nov 4, 2022 01:06 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Disposition to issuerCommon Stock | 1,004 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-035039 · doc4.xml · nonDerivative · entry 1 Patel Sunil · CIK 0001503062 · Former Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,820 F1 · kind: Certain of the Reporting Person's equity awards were cancelled in connection with the separation of OmniAb, Inc. from the Issuer on November 1, 2022. F1 · price: Certain of the Reporting Person's equity awards were cancelled in connection with the separation of OmniAb, Inc. from the Issuer on November 1, 2022. Read SEC document |
| November 01, 2022 Filed Nov 3, 2022 21:14 UTC | OmniAb, Inc. OABI · Entity 5294 | GrantStock Option · Derivative | 37,840 | Not disclosed Strike: $9.10 | Not disclosed |
DisclosureSEC source: 0000899243-22-035058 · doc4.xml · derivative · entry 10 Patel Sunil · CIK 0001503062 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,840 Underlying: Common Stock · 37,840 shares Expires 2032-06-10 F1 · kind: Pursuant to the business combination of Avista Public Acquisition Corp. II and OmniAb, Inc. ("Legacy OmniAb"), as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of Legacy OmniAb automatically converted into the right to receive securities of the Issuer with the same terms and conditions in accordance with an exchange ratio described in the Merger Agreement. F1 · price: Pursuant to the business combination of Avista Public Acquisition Corp. II and OmniAb, Inc. ("Legacy OmniAb"), as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of Legacy OmniAb automatically converted into the right to receive securities of the Issuer with the same terms and conditions in accordance with an exchange ratio described in the Merger Agreement. F5 · derivative.exercise_date: The stock option fully vests on the earlier of (i) the date of the next annual meeting of the Issuer's stockholders or (ii) on June 10, 2023. Read SEC document |
| November 01, 2022 Filed Nov 3, 2022 21:14 UTC | OmniAb, Inc. OABI · Entity 5294 | GrantStock Option · Derivative | 13,994 | Not disclosed Strike: $13.24 | Not disclosed |
DisclosureSEC source: 0000899243-22-035058 · doc4.xml · derivative · entry 9 Patel Sunil · CIK 0001503062 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,994 Underlying: Common Stock · 13,994 shares Expires 2031-06-04 F1 · kind: Pursuant to the business combination of Avista Public Acquisition Corp. II and OmniAb, Inc. ("Legacy OmniAb"), as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of Legacy OmniAb automatically converted into the right to receive securities of the Issuer with the same terms and conditions in accordance with an exchange ratio described in the Merger Agreement. F1 · price: Pursuant to the business combination of Avista Public Acquisition Corp. II and OmniAb, Inc. ("Legacy OmniAb"), as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of Legacy OmniAb automatically converted into the right to receive securities of the Issuer with the same terms and conditions in accordance with an exchange ratio described in the Merger Agreement. F4 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document |
| November 01, 2022 Filed Nov 3, 2022 21:14 UTC | OmniAb, Inc. OABI · Entity 5294 | GrantStock Option · Derivative | 10,565 | Not disclosed Strike: $13.49 | Not disclosed |
DisclosureSEC source: 0000899243-22-035058 · doc4.xml · derivative · entry 8 Patel Sunil · CIK 0001503062 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,565 Underlying: Common Stock · 10,565 shares Expires 2030-06-10 F1 · kind: Pursuant to the business combination of Avista Public Acquisition Corp. II and OmniAb, Inc. ("Legacy OmniAb"), as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of Legacy OmniAb automatically converted into the right to receive securities of the Issuer with the same terms and conditions in accordance with an exchange ratio described in the Merger Agreement. F1 · price: Pursuant to the business combination of Avista Public Acquisition Corp. II and OmniAb, Inc. ("Legacy OmniAb"), as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of Legacy OmniAb automatically converted into the right to receive securities of the Issuer with the same terms and conditions in accordance with an exchange ratio described in the Merger Agreement. F4 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document |
| November 01, 2022 Filed Nov 3, 2022 21:14 UTC | OmniAb, Inc. OABI · Entity 5294 | GrantStock Option · Derivative | 17,427 | Not disclosed Strike: $13.03 | Not disclosed |
DisclosureSEC source: 0000899243-22-035058 · doc4.xml · derivative · entry 7 Patel Sunil · CIK 0001503062 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,427 Underlying: Common Stock · 17,427 shares Expires 2029-06-06 F1 · kind: Pursuant to the business combination of Avista Public Acquisition Corp. II and OmniAb, Inc. ("Legacy OmniAb"), as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of Legacy OmniAb automatically converted into the right to receive securities of the Issuer with the same terms and conditions in accordance with an exchange ratio described in the Merger Agreement. F1 · price: Pursuant to the business combination of Avista Public Acquisition Corp. II and OmniAb, Inc. ("Legacy OmniAb"), as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of Legacy OmniAb automatically converted into the right to receive securities of the Issuer with the same terms and conditions in accordance with an exchange ratio described in the Merger Agreement. F4 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document |
| November 01, 2022 Filed Nov 3, 2022 21:14 UTC | OmniAb, Inc. OABI · Entity 5294 | GrantStock Option · Derivative | 10,590 | Not disclosed Strike: $22.47 | Not disclosed |
DisclosureSEC source: 0000899243-22-035058 · doc4.xml · derivative · entry 6 Patel Sunil · CIK 0001503062 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,590 Underlying: Common Stock · 10,590 shares Expires 2028-06-19 F1 · kind: Pursuant to the business combination of Avista Public Acquisition Corp. II and OmniAb, Inc. ("Legacy OmniAb"), as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of Legacy OmniAb automatically converted into the right to receive securities of the Issuer with the same terms and conditions in accordance with an exchange ratio described in the Merger Agreement. F1 · price: Pursuant to the business combination of Avista Public Acquisition Corp. II and OmniAb, Inc. ("Legacy OmniAb"), as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of Legacy OmniAb automatically converted into the right to receive securities of the Issuer with the same terms and conditions in accordance with an exchange ratio described in the Merger Agreement. F4 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document |
| November 01, 2022 Filed Nov 3, 2022 21:14 UTC | OmniAb, Inc. OABI · Entity 5294 | GrantStock Option · Derivative | 10,513 | Not disclosed Strike: $13.02 | Not disclosed |
DisclosureSEC source: 0000899243-22-035058 · doc4.xml · derivative · entry 5 Patel Sunil · CIK 0001503062 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,513 Underlying: Common Stock · 10,513 shares Expires 2027-05-25 F1 · kind: Pursuant to the business combination of Avista Public Acquisition Corp. II and OmniAb, Inc. ("Legacy OmniAb"), as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of Legacy OmniAb automatically converted into the right to receive securities of the Issuer with the same terms and conditions in accordance with an exchange ratio described in the Merger Agreement. F1 · price: Pursuant to the business combination of Avista Public Acquisition Corp. II and OmniAb, Inc. ("Legacy OmniAb"), as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of Legacy OmniAb automatically converted into the right to receive securities of the Issuer with the same terms and conditions in accordance with an exchange ratio described in the Merger Agreement. F4 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document |
| November 01, 2022 Filed Nov 3, 2022 21:14 UTC | OmniAb, Inc. OABI · Entity 5294 | GrantStock Option · Derivative | 9,970 | Not disclosed Strike: $13.69 | Not disclosed |
DisclosureSEC source: 0000899243-22-035058 · doc4.xml · derivative · entry 4 Patel Sunil · CIK 0001503062 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,970 Underlying: Common Stock · 9,970 shares Expires 2026-05-23 F1 · kind: Pursuant to the business combination of Avista Public Acquisition Corp. II and OmniAb, Inc. ("Legacy OmniAb"), as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of Legacy OmniAb automatically converted into the right to receive securities of the Issuer with the same terms and conditions in accordance with an exchange ratio described in the Merger Agreement. F1 · price: Pursuant to the business combination of Avista Public Acquisition Corp. II and OmniAb, Inc. ("Legacy OmniAb"), as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of Legacy OmniAb automatically converted into the right to receive securities of the Issuer with the same terms and conditions in accordance with an exchange ratio described in the Merger Agreement. F4 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document |
| November 01, 2022 Filed Nov 3, 2022 21:14 UTC | OmniAb, Inc. OABI · Entity 5294 | GrantStock Option · Derivative | 11,789 | Not disclosed Strike: $10.30 | Not disclosed |
DisclosureSEC source: 0000899243-22-035058 · doc4.xml · derivative · entry 3 Patel Sunil · CIK 0001503062 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,789 Underlying: Common Stock · 11,789 shares Expires 2025-04-24 F1 · kind: Pursuant to the business combination of Avista Public Acquisition Corp. II and OmniAb, Inc. ("Legacy OmniAb"), as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of Legacy OmniAb automatically converted into the right to receive securities of the Issuer with the same terms and conditions in accordance with an exchange ratio described in the Merger Agreement. F1 · price: Pursuant to the business combination of Avista Public Acquisition Corp. II and OmniAb, Inc. ("Legacy OmniAb"), as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of Legacy OmniAb automatically converted into the right to receive securities of the Issuer with the same terms and conditions in accordance with an exchange ratio described in the Merger Agreement. F4 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document |
| November 01, 2022 Filed Nov 3, 2022 21:14 UTC | OmniAb, Inc. OABI · Entity 5294 | GrantStock Option · Derivative | 14,178 | Not disclosed Strike: $7.75 | Not disclosed |
DisclosureSEC source: 0000899243-22-035058 · doc4.xml · derivative · entry 2 Patel Sunil · CIK 0001503062 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,178 Underlying: Common Stock · 14,178 shares Expires 2024-06-04 F1 · kind: Pursuant to the business combination of Avista Public Acquisition Corp. II and OmniAb, Inc. ("Legacy OmniAb"), as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of Legacy OmniAb automatically converted into the right to receive securities of the Issuer with the same terms and conditions in accordance with an exchange ratio described in the Merger Agreement. F1 · price: Pursuant to the business combination of Avista Public Acquisition Corp. II and OmniAb, Inc. ("Legacy OmniAb"), as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of Legacy OmniAb automatically converted into the right to receive securities of the Issuer with the same terms and conditions in accordance with an exchange ratio described in the Merger Agreement. F4 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document |
| November 01, 2022 Filed Nov 3, 2022 21:14 UTC | OmniAb, Inc. OABI · Entity 5294 | GrantCommon Stock | 172,512 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-035058 · doc4.xml · nonDerivative · entry 1 Patel Sunil · CIK 0001503062 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 172,512 F1 · kind: Pursuant to the business combination of Avista Public Acquisition Corp. II and OmniAb, Inc. ("Legacy OmniAb"), as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of Legacy OmniAb automatically converted into the right to receive securities of the Issuer with the same terms and conditions in accordance with an exchange ratio described in the Merger Agreement. F2 · shares: Includes 8,753 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock and does not expire. F3 · shares: Includes 22,538 earn-out shares subject to forfeiture provisions described in the Merger Agreement. F1 · price: Pursuant to the business combination of Avista Public Acquisition Corp. II and OmniAb, Inc. ("Legacy OmniAb"), as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of Legacy OmniAb automatically converted into the right to receive securities of the Issuer with the same terms and conditions in accordance with an exchange ratio described in the Merger Agreement. Read SEC document |
| June 10, 2022 Filed Jun 13, 2022 22:45 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 4,340 | $0.00 Strike: $79.29 | $0.00 |
DisclosureSEC source: 0000886163-22-000078 · edgardoc.xml · derivative · entry 2 Patel Sunil · CIK 0001503062 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,340 Underlying: Common Stock · 4,340 shares Expires 2032-06-10 F2 · derivative.exercise_date: Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 10, 2022. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant. Read SEC document |
| June 10, 2022 Filed Jun 13, 2022 22:45 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantCommon Stock | 1,004 | $0.00 | $0.00 |
DisclosureSEC source: 0000886163-22-000078 · edgardoc.xml · nonDerivative · entry 1 Patel Sunil · CIK 0001503062 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,824 F1 · shares: Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 10, 2022. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant. Read SEC document |
| June 04, 2021 Filed Jun 8, 2021 01:23 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 3,269 | $0.00 Strike: $115.39 | $0.00 |
DisclosureSEC source: 0000886163-21-000088 · edgardoc.xml · derivative · entry 2 Patel Sunil · CIK 0001503062 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,269 Underlying: Common Stock · 3,269 shares Expires 2031-06-04 F2 · derivative.exercise_date: Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 04, 2021. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant. Read SEC document |
| June 04, 2021 Filed Jun 8, 2021 01:23 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantCommon Stock | 630 | $0.00 | $0.00 |
DisclosureSEC source: 0000886163-21-000088 · edgardoc.xml · nonDerivative · entry 1 Patel Sunil · CIK 0001503062 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,820 F1 · shares: Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 04, 2021. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant. Read SEC document |
| November 02, 2020 Filed Nov 4, 2020 21:19 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | PurchaseCommon Stock | 1,000 | $82.52 | $82,520.00 |
DisclosureSEC source: 0000886163-20-000118 · edgardoc.xml · nonDerivative · entry 1 Patel Sunil · CIK 0001503062 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,190 Read SEC document |
| June 10, 2020 Filed Jun 12, 2020 22:32 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 2,468 | $0.00 Strike: $117.58 | $0.00 |
DisclosureSEC source: 0000886163-20-000074 · edgardoc.xml · derivative · entry 2 Patel Sunil · CIK 0001503062 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,468 Underlying: Common Stock · 2,468 shares Expires 2030-06-10 F2 · derivative.exercise_date: Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 10, 2020. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant. Read SEC document |
| June 10, 2020 Filed Jun 12, 2020 22:32 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantCommon Stock | 831 | $0.00 | $0.00 |
DisclosureSEC source: 0000886163-20-000074 · edgardoc.xml · nonDerivative · entry 1 Patel Sunil · CIK 0001503062 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,190 F1 · shares: Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 10, 2020. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant. Read SEC document |
| August 02, 2019 Filed Aug 5, 2019 22:56 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | PurchaseCommon Stock | 1,000 | $95.98 | $95,980.00 |
DisclosureSEC source: 0000886163-19-000136 · edgardoc.xml · nonDerivative · entry 1 Patel Sunil · CIK 0001503062 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,359 Read SEC document |
| June 06, 2019 Filed Jun 7, 2019 22:44 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 4,071 | $0.00 Strike: $113.59 | $0.00 |
DisclosureSEC source: 0000886163-19-000103 · edgardoc.xml · derivative · entry 2 Patel Sunil · CIK 0001503062 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,071 Underlying: Common Stock · 4,071 shares Expires 2029-06-06 F2 · derivative.exercise_date: Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 06, 2019. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant. Read SEC document |
| June 06, 2019 Filed Jun 7, 2019 22:44 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantCommon Stock | 835 | $0.00 | $0.00 |
DisclosureSEC source: 0000886163-19-000103 · edgardoc.xml · nonDerivative · entry 1 Patel Sunil · CIK 0001503062 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,359 F1 · shares: Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 06, 2019. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant. Read SEC document |
| August 16, 2018 Filed Aug 17, 2018 23:37 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 7,335 | $0.00 Strike: $32.30 | $0.00 |
DisclosureSEC source: 0000886163-18-000120 · edgardoc.xml · derivative · entry 9 Patel Sunil · CIK 0001503062 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,335 shares Expires 2023-06-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 11, 2013, and fully vested on the first anniversary of the grant date. Read SEC document |
| August 16, 2018 Filed Aug 17, 2018 23:37 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 7,335 | $0.00 Strike: $12.53 | $0.00 |
DisclosureSEC source: 0000886163-18-000120 · edgardoc.xml · derivative · entry 8 Patel Sunil · CIK 0001503062 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,335 shares Expires 2022-05-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Acquired by a grant of the Board of Directors of the Company at their annual meeting on May 31, 2012, and fully vested on the first anniversary of the grant date. Read SEC document |
| August 16, 2018 Filed Aug 17, 2018 23:37 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 7,335 | $0.00 Strike: $10.12 | $0.00 |
DisclosureSEC source: 0000886163-18-000120 · edgardoc.xml · derivative · entry 7 Patel Sunil · CIK 0001503062 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,335 shares Expires 2021-06-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 01, 2011, and fully vested on the first anniversary of the grant date. Read SEC document |
| August 16, 2018 Filed Aug 17, 2018 23:37 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $9.60 | $0.00 |
DisclosureSEC source: 0000886163-18-000120 · edgardoc.xml · derivative · entry 6 Patel Sunil · CIK 0001503062 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2020-10-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option becomes exercisable in 36 successive monthly installments upon completion of each calendar month of service beginning on the grant date. Read SEC document |
| August 16, 2018 Filed Aug 17, 2018 23:37 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 42,287 | $240.05 | $10,150,808.29 |
DisclosureSEC source: 0000886163-18-000120 · edgardoc.xml · nonDerivative · entry 5 Patel Sunil · CIK 0001503062 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,524 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $238.31 to $242.68, inclusive. The reporting person undertakes to provide, upon request to the Securities Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 16, 2018 Filed Aug 17, 2018 23:37 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionCommon Stock | 7,335 | $32.30 | $236,920.50 |
DisclosureSEC source: 0000886163-18-000120 · edgardoc.xml · nonDerivative · entry 4 Patel Sunil · CIK 0001503062 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,811 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 16, 2018 Filed Aug 17, 2018 23:37 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionCommon Stock | 7,335 | $12.53 | $91,907.55 |
DisclosureSEC source: 0000886163-18-000120 · edgardoc.xml · nonDerivative · entry 3 Patel Sunil · CIK 0001503062 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,476 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 16, 2018 Filed Aug 17, 2018 23:37 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionCommon Stock | 7,335 | $10.12 | $74,230.20 |
DisclosureSEC source: 0000886163-18-000120 · edgardoc.xml · nonDerivative · entry 2 Patel Sunil · CIK 0001503062 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,141 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 16, 2018 Filed Aug 17, 2018 23:37 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionCommon Stock | 5,000 | $9.60 | $48,000.00 |
DisclosureSEC source: 0000886163-18-000120 · edgardoc.xml · nonDerivative · entry 1 Patel Sunil · CIK 0001503062 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,806 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 19, 2018 Filed Jun 21, 2018 20:46 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 2,474 | $0.00 Strike: $76.77 | $0.00 |
DisclosureSEC source: 0000899243-18-017610 · doc4.xml · derivative · entry 2 Patel Sunil · CIK 0001503062 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,474 Underlying: Common Stock · 2,474 shares Expires 2028-06-18 F1 · derivative.exercise_date: Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 19, 2018. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant. Read SEC document |
| June 19, 2018 Filed Jun 21, 2018 20:46 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantCommon Stock | 493 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-017610 · doc4.xml · nonDerivative · entry 1 Patel Sunil · CIK 0001503062 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,806 F1 · shares: Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 19, 2018. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant. Read SEC document |
| June 19, 2018 Filed Jul 3, 2018 22:37 UTC Amendment | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 2,474 | $0.00 Strike: $195.91 | $0.00 |
DisclosureSEC source: 0000886163-18-000095 · edgardoc.xml · derivative · entry 1 Patel Sunil · CIK 0001503062 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,474 Underlying: Common Stock · 2,474 shares Expires 2028-06-18 F1 · derivative.exercise_price: This amendment is being filed to correct the exercise price listed in item 2 of Table II in order to reflect the market closing price on the grant date. F2 · derivative.exercise_date: Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 19, 2018. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant. Read SEC document |
| January 04, 2018 Filed Jan 8, 2018 19:09 UTC | OncoMed Pharmaceuticals Inc OMED · Entity 158190 | GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $3.98 | $0.00 |
DisclosureSEC source: 0001140361-18-001275 · doc1.xml · derivative · entry 1 Patel Sunil · CIK 0001503062 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2028-01-03 F1 · derivative.exercise_date: The option vests with respect to 1/48 of the shares subject thereto on each monthly anniversary of the date of grant, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date. Read SEC document |
| October 10, 2017 Filed Oct 12, 2017 18:36 UTC | OncoMed Pharmaceuticals Inc OMED · Entity 158190 | SaleCommon Stock | 1,202 | $4.24 | $5,098.64 |
DisclosureSEC source: 0001140361-17-038568 · doc1.xml · nonDerivative · entry 2 Patel Sunil · CIK 0001503062 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,336 F1 · kind: Pursuant to a sell-to-cover election made by the Reporting Person at the time of the initial grant of the restricted stock unit ("RSU") award, the shares were sold upon the vesting of restricted stock units solely to cover applicable withholding taxes. F2 · balance_after: Includes 54,375 RSUs. The Reporting Person is entitled to receive one (1) share of common stock of the issuer for each one (1) RSU upon the vesting thereof. Read SEC document |
| October 10, 2017 Filed Oct 12, 2017 18:36 UTC | OncoMed Pharmaceuticals Inc OMED · Entity 158190 | SaleCommon Stock | 46 | $4.27 | $196.42 |
DisclosureSEC source: 0001140361-17-038568 · doc1.xml · nonDerivative · entry 1 Patel Sunil · CIK 0001503062 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,538 F1 · kind: Pursuant to a sell-to-cover election made by the Reporting Person at the time of the initial grant of the restricted stock unit ("RSU") award, the shares were sold upon the vesting of restricted stock units solely to cover applicable withholding taxes. F2 · balance_after: Includes 54,375 RSUs. The Reporting Person is entitled to receive one (1) share of common stock of the issuer for each one (1) RSU upon the vesting thereof. Read SEC document |
| October 07, 2017 Filed Oct 10, 2017 19:28 UTC | OncoMed Pharmaceuticals Inc OMED · Entity 158190 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $4.36 | $0.00 |
DisclosureSEC source: 0001140361-17-038099 · doc1.xml · derivative · entry 2 Patel Sunil · CIK 0001503062 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2027-10-06 F3 · derivative.exercise_date: The option vests with respect to 1/48 of the shares subject thereto on each monthly anniversary of the date of grant, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date. Read SEC document |
| October 07, 2017 Filed Oct 10, 2017 19:28 UTC | OncoMed Pharmaceuticals Inc OMED · Entity 158190 | GrantCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-038099 · doc1.xml · nonDerivative · entry 1 Patel Sunil · CIK 0001503062 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,584 F1 · shares: Restricted stock units ("RSUs"). The reporting person is entitled to receive one (1) share of common stock of the issuer for each one (1) RSU upon the vesting thereof. F2 · balance_after: Includes 57,500 RSUs. Read SEC document |
| May 25, 2017 Filed May 27, 2017 00:17 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 2,456 | $113.50 Strike: $113.50 | $278,756.00 |
DisclosureSEC source: 0000886163-17-000074 · edgardoc.xml · derivative · entry 2 Patel Sunil · CIK 0001503062 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,456 Underlying: Common Stock · 2,456 shares Expires 2027-05-25 F2 · derivative.exercise_date: Acquired by a grant of the Board of Directors of the Company at their annual meeting on May 25, 2017. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant. Read SEC document |
| May 25, 2017 Filed May 27, 2017 00:17 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantCommon Stock | 666 | $0.00 | $0.00 |
DisclosureSEC source: 0000886163-17-000074 · edgardoc.xml · nonDerivative · entry 1 Patel Sunil · CIK 0001503062 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,313 F1 · shares: Acquired by a grant of the Board of Directors of the Company at their annual meeting on May 25, 2017 Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant. Read SEC document |
| April 23, 2017 Filed Apr 25, 2017 18:12 UTC | OncoMed Pharmaceuticals Inc OMED · Entity 158190 | GrantStock Option (Right to Buy) · Derivative | 60,000 | $0.00 Strike: $3.73 | $0.00 |
DisclosureSEC source: 0001140361-17-016767 · doc1.xml · derivative · entry 2 Patel Sunil · CIK 0001503062 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2027-04-22 F3 · derivative.exercise_date: The option vests with respect to 1/48 of the shares subject thereto on each monthly anniversary of the date of grant, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date. Read SEC document |
| April 23, 2017 Filed Apr 25, 2017 18:12 UTC | OncoMed Pharmaceuticals Inc OMED · Entity 158190 | GrantCommon Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-016767 · doc1.xml · nonDerivative · entry 1 Patel Sunil · CIK 0001503062 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,584 F1 · shares: Restricted stock units ("RSUs"). The reporting person is entitled to receive one (1) share of common stock of the issuer for each one (1) RSU upon the vesting thereof. F2 · balance_after: Includes 32,500 RSUs. Read SEC document |
| April 04, 2017 Filed Apr 5, 2017 19:40 UTC | OncoMed Pharmaceuticals Inc OMED · Entity 158190 | SaleCommon Stock | 5,711 | $9.06 | $51,731.38 |
DisclosureSEC source: 0001140361-17-015048 · doc1.xml · nonDerivative · entry 2 Patel Sunil · CIK 0001503062 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,584 F1 · kind: Pursuant to a sell-to-cover election made by the Reporting Person at the time of the initial grant of the restricted stock unit award, the shares were sold upon the vesting of restricted stock units solely to cover applicable withholding taxes. F2 · balance_after: Includes 12,500 restricted stock units ("RSUs"). The reporting person is entitled to receive one (1) share of common stock of the issuer for each one (1) RSU upon the vesting thereof. Read SEC document |
| April 04, 2017 Filed Apr 5, 2017 19:40 UTC | OncoMed Pharmaceuticals Inc OMED · Entity 158190 | SaleCommon Stock | 43 | $8.87 | $381.59 |
DisclosureSEC source: 0001140361-17-015048 · doc1.xml · nonDerivative · entry 1 Patel Sunil · CIK 0001503062 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,295 F1 · kind: Pursuant to a sell-to-cover election made by the Reporting Person at the time of the initial grant of the restricted stock unit award, the shares were sold upon the vesting of restricted stock units solely to cover applicable withholding taxes. F2 · balance_after: Includes 12,500 restricted stock units ("RSUs"). The reporting person is entitled to receive one (1) share of common stock of the issuer for each one (1) RSU upon the vesting thereof. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.